Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Feature|Podcasts|March 24, 2025
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
Author(s)Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
Advertisement
In this Pharmaceutical Executive podcast episode, UpScriptHealth founder and CEO Peter Ax discusses:
- The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications
- How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts
- How digital health platforms can help potentially offset tariff impacts
- The importance of telehealth in ensuring medication availability
- Strategic partnerships between digital health platforms and pharma companies to improve patient care and access
- and more
Advertisement
Related to this article
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Advertisement
Advertisement
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5